全文获取类型
收费全文 | 5040篇 |
免费 | 334篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 101篇 |
妇产科学 | 62篇 |
基础医学 | 767篇 |
口腔科学 | 43篇 |
临床医学 | 498篇 |
内科学 | 1269篇 |
皮肤病学 | 37篇 |
神经病学 | 480篇 |
特种医学 | 273篇 |
外科学 | 840篇 |
综合类 | 8篇 |
一般理论 | 6篇 |
预防医学 | 278篇 |
眼科学 | 38篇 |
药学 | 309篇 |
中国医学 | 3篇 |
肿瘤学 | 333篇 |
出版年
2023年 | 43篇 |
2022年 | 85篇 |
2021年 | 219篇 |
2020年 | 99篇 |
2019年 | 163篇 |
2018年 | 200篇 |
2017年 | 134篇 |
2016年 | 147篇 |
2015年 | 156篇 |
2014年 | 226篇 |
2013年 | 285篇 |
2012年 | 422篇 |
2011年 | 420篇 |
2010年 | 216篇 |
2009年 | 199篇 |
2008年 | 295篇 |
2007年 | 285篇 |
2006年 | 231篇 |
2005年 | 221篇 |
2004年 | 159篇 |
2003年 | 167篇 |
2002年 | 124篇 |
2001年 | 72篇 |
2000年 | 65篇 |
1999年 | 59篇 |
1998年 | 29篇 |
1997年 | 17篇 |
1996年 | 19篇 |
1995年 | 26篇 |
1994年 | 15篇 |
1993年 | 17篇 |
1992年 | 52篇 |
1991年 | 41篇 |
1990年 | 54篇 |
1989年 | 45篇 |
1988年 | 40篇 |
1987年 | 34篇 |
1986年 | 32篇 |
1985年 | 35篇 |
1984年 | 22篇 |
1983年 | 23篇 |
1980年 | 13篇 |
1979年 | 19篇 |
1978年 | 16篇 |
1977年 | 13篇 |
1975年 | 11篇 |
1974年 | 13篇 |
1972年 | 10篇 |
1968年 | 11篇 |
1967年 | 12篇 |
排序方式: 共有5390条查询结果,搜索用时 0 毫秒
61.
Benjamin Fournier Maud Tusseau Marine Villard Christophe Malcus Emilie Chopin Emmanuel Martin Debora Jorge Cordeiro Nicole Fabien Mathieu Fusaro Alexandra Gauthier Nathalie Garnier David Goncalves Sonia Lounis Christelle Lenoir Anne-Laure Mathieu Marion Moreews Magali Perret Capucine Picard Sylvain Latour 《The Journal of allergy and clinical immunology》2021,147(2):740-743.e9
62.
63.
64.
Benoit Peyronnet Emmanuel Oger Zineddine Khene Gregory Verhoest Romain Mathieu Mathieu Roumiguié Jean-Baptiste Beauval Benjamin Pradere Alexandra Masson-Lecomte Christophe Vaessen Hervé Baumert Jean-Christophe Bernhard Nicolas Doumerc Stéphane Droupy Franck Bruyere Alexandre De La Taille Morgan Roupret Karim Bensalah 《World journal of urology》2015,33(11):1815-1820
65.
66.
Clinical benefits of non‐taxane chemotherapies in unselected patients with symptomatic metastatic castration‐resistant prostate cancer after docetaxel: the GETUG‐P02 study 下载免费PDF全文
Florence Joly Remy Delva Loïc Mourey Emmanuel Sevin Emmanuelle Bompas Lionel Vedrine Alain Ravaud Jean‐Christophe Eymard Nicole Tubiana‐Mathieu Claude Linassier Nadine Houede Aline Guillot François Ringensen Oana Cojocarasu Bruno Valenza Alexandra Leconte Stéphanie Lheureux Bénédicte Clarisse Stéphane Oudard 《BJU international》2015,115(1):65-73
67.
68.
69.
Simone Susser Mathieu Flinders Henk W. Reesink Stefan Zeuzem Glenn Lawyer Anne Ghys Veerle Van Eygen James Witek Sandra De Meyer Christoph Sarrazin 《Antimicrobial agents and chemotherapy》2015,59(5):2746-2755
In treating hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections, the rapid reselection of resistance-associated variants (RAVs) is well known in patients with repeated exposure to the same class of antiviral agents. For chronic hepatitis C patients who have experienced virologic failure with direct-acting antiviral drugs, the potential for the reselection of persistent RAVs is unknown. Nine patients who received 14 days of telaprevir monotherapy were retreated with telaprevir-based triple therapy 4.3 to 5.7 years later. In four patients with virologic failure with both telaprevir-containing regimens, population-based and deep sequencing (454 GS-FLX) of the NS3 protease gene were performed before and at treatment failure (median coverage, 4,651 reads). Using deep sequencing, with a threshold of 1.0% for variant calling, no isolates were found harboring RAVs at the baseline time points. While population-based sequencing uncovered similar resistance patterns (V36M plus R155K for subtype 1a and V36A for subtype 1b) in all four patients after the first and second telaprevir treatments, deep sequencing analysis revealed a median of 7 (range, 4 to 23) nucleotide substitutions on the NS3 backbone of the resistant strains, together with large phylogenetic differences between viral quasispecies, making the survival of resistant isolates highly unlikely. In contrast, in a comparison of the two baseline time points, the median number of nucleotide exchanges in the wild-type isolates was only 3 (range, 2 to 8), reflecting the natural evolution of the NS3 gene. In patients with repeated direct antiviral treatment, a continuous evolution of HCV quasispecies was observed, with no clear evidence of persistence and reselection but strong signs of independent de novo generation of resistance. Antiviral therapy for chronic viral infections, like HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV), faces several challenges. These viruses have evolved survival strategies and proliferate by escaping the host''s immune system. The development of direct-acting antiviral agents is an important achievement in fighting these infections. Viral variants conferring resistance to direct antiviral drugs lead to treatment failure. For HIV/HBV, it is well known that viral variants associated with treatment failure will be archived and reselected rapidly during retreatment with the same drug/class of drugs. We explored the mechanisms and rules of how resistant variants are selected and potentially reselected during repeated direct antiviral therapies in chronically HCV-infected patients. Interestingly, in contrast to HIV and HBV, we could not prove long-term persistence and reselection of resistant variants in HCV patients who failed protease inhibitor-based therapy. This may have important implications for the potential to reuse direct-acting antivirals in patients who failed the initial direct antiviral treatment. (The phase IIIb study described in this paper is registered at ClinicalTrials.gov under registration number .) NCT01054573相似文献
70.
Samuel Michael Lipski Georges Casimir Martine Vanlommel Mathieu Jeanmaire Pierre Dolhen 《Clinical Case Reports》2015,3(2):126-130
C1 esterase inhibitor (Berinert®) is generally used to treat severe attack of hereditary angioedema. We describe here the case of a patient who presented with a severe angioedema induced by angiotensin‐converting enzyme inhibitors (ACEIs) endangering her life. It could be successfully treated with that medicine. 相似文献